EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Trials and tribulations with artificial liver support






Gut 19(6): 578-583

Trials and tribulations with artificial liver support

The experience gained over the past few years in 2 techniques of liver support, charcoal hemoperfusion and polyacrylonitrile (PAN) membrane hemodialysis was reviewed. Problems with charcoal hemoperfusion have centered around platelet aggregation and hypertension, and new C preparations with a variety of different coatings to overcome these problems are described. Hemodialysis using the PAN membrane has caused fewer side-effects in patients and current results show that 33% of patients so treated recover consciousness. The new techniques for liver support currently being developed, including combined dialysis/perfusion systems and those based on plasma separation, are also described.


Accession: 006840601

PMID: 355070

DOI: 10.1136/gut.19.6.578



Related references

Gan, S.Khee.; Adams, L.A.; Watts, G.F., 2008: The trials and tribulations of the treatment of nonalcoholic fatty-liver disease. To review published clinical trials, with a focus on those of randomized design, of the management of nonalcoholic fatty-liver disease (NAFLD), an increasing complication of the obesity epidemic. There is increasing recognition that cardiovascular...

Fan, S.T., 2005: Liver transplantation in the Asia Pacific region--trials and tribulations. Medical Journal of Malaysia 60 Suppl B: 1-4

Raju, R.; Chau, D.; Verfaillie, C.M.; Hu, W-Shou., 2014: The road to regenerative liver therapies: the triumphs, trials and tribulations. The liver is one of the few organs that possess a high capacity to regenerate after liver failure or liver damage. The parenchymal cells of the liver, hepatocytes, contribute to the majority of the regeneration process. Thus, hepatocyte transplant...

Morris, R.E.; Brown, B.W., 1995: Tacrolimus for prevention of liver allograft rejection: clinical trials and tribulations. Lancet 346(8986): 1310-1311

Nyberg, S.L.; Shatford, R.A.; Hu, W.S.; Payne, W.D.; Cerra, F.B., 1992: Hepatocyte culture systems for artificial liver support: implications for critical care medicine (bioartificial liver support). Objective: The primary purpose of this review article is to familiarize critical care practitioners with newly developing techniques of hybrid artificial liver support. Implantable and extracorporeal hepatocyte culture systems are emphasized based...

James, M.I.; Howells, L.M.; Karmokar, A.; Higgins, J.A.; Greaves, P.; Cai, H.; Dennison, A.; Metcalfe, M.; Garcea, G.; Lloyd, D.M.; Berry, D.P.; Steward, W.P.; Brown, K., 2016: Characterization and propagation of tumor initiating cells derived from colorectal liver metastases: trials, tribulations and a cautionary note. Tumor initiating cells (TIC) are increasingly being put forward as a potential target for intervention within colorectal cancer. Whilst characterisation and outgrowth of these cells has been extensively undertaken in primary colorectal cancers, fe...

Kasai, S.; Sawa, M.; Mito, M., 1994: Is the biological artificial liver clinically applicable? A historic review of biological artificial liver support systems. Hemoperfusion, hemodiafiltration, plasma exchange, and extracorporeal liver perfusion have already been adopted to treat patients with acute and chronic hepatic failure. However, the survival rate of patients with acute hepatic failure remains at...

Kasai, S.I.hi; Sawa, M.; Mito, M., 1994: Is the biological artificial liver clinically applicable? A historic review of biological artificial liver support systems. Hemoperfusion, hemodiafiltration, plasma exchange, and extracorporeal liver perfusion have already been adopted to treat patients with acute and chronic hepatic failure. However, the survival rate of patients with acute hepatic failure remains at...

Chang, T.M., 1992: Artificial liver support based on artificial cells with emphasis on encapsulated hepatocytes. Artificial liver support requires more than a detoxification system. We have investigated additional approaches. Microencapsulated hepatocytes increased the survival time of fulminant hepatic failure (FHF) rats. They also lowered the bilirubin in...

Johnson, J.A.; Yasui, Y., 2010: Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations. Diabetologia 53(9): 1823-1826